Prognostic Factors and Adjuvant Treatments for Surgically Treated Cancers of the Biliary Tract: A Multicentre Study of the Anatolian Society of Medical Oncology (ASMO)

Basit Öğe Kaydı
dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorOztop, Ilhan
dc.contributor.authorKos, Tugba
dc.contributor.authorTuran, Nedim
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorHelvaci, Kaan
dc.contributor.authorBerk, Veli
dc.date.accessioned2024-04-24T17:28:18Z
dc.date.available2024-04-24T17:28:18Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Biliary tract cancers are rare, and surgical resection is the standard treatment at early stages. However, reports on the benefits of adjuvant treatment following surgical resection are conflicting. This study aimed to evaluate the factors affecting survival and adjuvant treatments in patients with surgically treated biliary tract cancers. Materials and Methods: Patient clinical features, adjuvant treatments, and efficacy and prognostic factor data were evaluated. Survival analyses were performed using SPSS 15.0. Results: The median overall survival was 30.7 months (95% confidence interval [CI], 18.4-42.9 months). Median survival was 19 months (95% CI, 6-33) for patients treated with fluorouracil based chemotherapy and 53 months (95% CI, 33.2-78.8) with gemcitabine based chemotherapy (p=0.033). On univariate analysis, poor prognostic factors for survival were galbladder localization, perineural invasion, hepatic invasion, a lack of adjuvant chemoradiotherapy treatment, and a lack of lymph node dissection. On multivariate analysis, perineural invasion was a poor prognostic factor (p=0.008). Conclusions: Biliary tract cancers generally have poor prognoses. The main factors affecting survival are tumour localization, perineural invasion, hepatic invasion, adjuvant chemoradiotherapy, and lymph node dissection. Gemcitabine-based adjuvant chemotherapy is more effective than 5-fluorouracil-based chemotherapy.en_US
dc.identifier.doi10.7314/APJCP.2014.15.22.9687
dc.identifier.endpage9692en_US
dc.identifier.issn1513-7368
dc.identifier.issue22en_US
dc.identifier.pmid25520089
dc.identifier.scopus2-s2.0-84921457123
dc.identifier.scopusqualityQ3
dc.identifier.startpage9687en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.22.9687
dc.identifier.urihttps://hdl.handle.net/11468/20397
dc.identifier.volume15en_US
dc.identifier.wosWOS:000351056900023
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiliary Tract Canceren_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectAdjuvant Chemoradiotherapyen_US
dc.subjectPrognostic Factorsen_US
dc.titlePrognostic Factors and Adjuvant Treatments for Surgically Treated Cancers of the Biliary Tract: A Multicentre Study of the Anatolian Society of Medical Oncology (ASMO)en_US
dc.titlePrognostic Factors and Adjuvant Treatments for Surgically Treated Cancers of the Biliary Tract: A Multicentre Study of the Anatolian Society of Medical Oncology (ASMO)
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu